U.S. Markets open in 1 hr 30 mins
  • S&P Futures

    4,344.50
    +3.00 (+0.07%)
     
  • Dow Futures

    33,996.00
    -59.00 (-0.17%)
     
  • Nasdaq Futures

    14,202.50
    +44.00 (+0.31%)
     
  • Russell 2000 Futures

    1,970.50
    -2.20 (-0.11%)
     
  • Crude Oil

    88.10
    +0.75 (+0.86%)
     
  • Gold

    1,808.20
    -21.50 (-1.18%)
     
  • Silver

    23.06
    -0.75 (-3.14%)
     
  • EUR/USD

    1.1159
    -0.0085 (-0.7588%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    30.98
    -0.18 (-0.58%)
     
  • GBP/USD

    1.3392
    -0.0071 (-0.5250%)
     
  • USD/JPY

    115.3190
    +0.6590 (+0.5747%)
     
  • BTC-USD

    36,725.50
    -1,133.79 (-2.99%)
     
  • CMC Crypto 200

    838.91
    -16.90 (-1.97%)
     
  • FTSE 100

    7,509.17
    +39.39 (+0.53%)
     
  • Nikkei 225

    26,170.30
    -841.00 (-3.11%)
     

Macrogenics: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MGNX

Shares of Macrogenics (NASDAQ:MGNX) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 27.47% over the past year to ($0.66), which beat the estimate of ($0.93).

Revenue of $18,253,000 declined by 2.60% from the same period last year, which beat the estimate of $15,790,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 04, 2020

View more earnings on MGNX

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/winmrboe

Price Action

52-week high: $32.18

Company's 52-week low was at $4.04

Price action over last quarter: down 17.09%

Company Profile

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.